Platelet adhesion onto artificial surfaces: Inhibition by benzamidine, pentamidine, and pyridoxal-5-phosphate as demonstrated by flow cytometric quantification of platelet adhesion to microspheres

Journal of Laboratory and Clinical Medicine

Volumn 131, Issue 1, 1998, Pages 84-92

  Gemmell, Cynthia H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0031885955     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2143(98)90081-6     Document Type: Article

References (32)

1. Hanson SR. Device thrombosis and thromboembolism. Cardiovasc Pathol 1993;2(suppl):157S-65S.
2. Gemmell CH, Ramirez SM, Yeo EL, Sefton MV. Platelet activation in whole blood by artificial surfaces: identification of platelet-derived microparticles and activated platelet binding to leukocytes as material-induced activation events. J Lab Clin Med 1995;125:276-87.
3. Sheppeck RA, Bentz M, Dickson C, Hribar S, White J, Janosky J, et al. Examination of the roles of glycoprotein Ib and glycoprotein IIb/IIIa in platelet deposition on an artificial surface using clinical antiplatelet agents and monoclonal antibody blockade. Blood 1991;78;673-80.
4. Johnson PC, Sheppeck RA, Hribar SR, Bentz ML, Janosky J, Dickson CS. Inhibition of platelet retention on artificial microvascular grafts with monoclonal antibodies and a high affinity peptide directed against platelet membrane glycoproteins. Arterioscler Thromb 1991;11:552-60.
5. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E. Platelet membrane glycoprotein IIb/IIIa: member of a family of Arg-Gly-Asp specific adhesion receptors. Science 1986;231:1559-62.
6. Lindon JN, McManama G, Kushner L, Merrill EW, Salzman EW. Does the conformation of adsorbed fibrinogen dictate platelet interactions with artificial surfaces? Blood 1986;68: 355-62.
7. Savage B, Ruggeri ZM. Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets. J Biol Chem 1991;266:11227-33.
8. Gartner TK, Amrani DL, Derrick JM, Kirschbaum NE, Matsueda GR, Taylor DB. Characterization of adhesion of "resting" and stimulated platelets to fibrinogen and its fragments. Thromb Res 1993;71:47-60.
9. Jacobs S, Cuatrecasas P. The mobile receptor hypothesis and "cooperativity" of hormone binding. Application to insulin. Biochim Biophys Acta 1976;433:482-95.
10. Peerschke EIB, Ghebrehiwet B. Platelet interactions with C1q in whole blood and in the presence of immune complexes or aggregated IgG. Clin Immunol Immunopathol 1992;63:45-50.
11. 3 integrins (GPIIb/IIIa) and the expression of P-selectin and procoagulant activity. J Exp Med 1993;178:579-87.
12. Sims PJ, Faioni EM, Wiedmer T, Shattil SJ. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem 1988;263:18205-12.
13. Ando B, Wiedmer T, Hamilton KK, Sims PJ. Complement proteins C5b-9 initiate secretion of platelet storage granules without increased binding of fibrinogen or von Willebrand factor to newly expressed cell surface GPIIb-IIIa. J Biol Chem 1988;263:11907-14.
14. Brash JL. The fate of fibrinogen following adsorption at the blood-biomaterial interface. Ann NY Acad Sci 1987;516:206-22.
15. Anderson GP, Anderson CL. Signal transduction by the platelet Fc-receptor. Blood 1990;76:1165-72.
16. Worthington RE, Carroll RC, Boucheix C. Platelet activation by CD9 monoclonal antibodies is mediated by the FcγII receptor. Br J Haematol 1990;74:216-22.
17. Weisman HF, Bartow T, Leppo MK, Marsh HC Jr., Carson GR, Concino MF, et al. Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science 1990;249:146-51.
18. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood 1996; 88:3432-45.
19. Asghar SS. Pharmacological manipulation of complement system. Pharmacol Rev 1984;36:223-44.
20. Bing DH, Cory M, Doll M. The inactivation of human C1 by benzamidine and pyridinium sulfonylfuorides. J Immunol 1974;113;584-90.
21. Andrew JM, Roman DP Jr., Bing DH. Inhibition of four human serine proteases by substituted benzamidines. J Med Chem 1978;21:1202-7.
22. Hauptmann J, Markwardt F. Inhibition of the haemolytic complement activity by derivatives of benzamidine. Biochem Pharmacol 1977;26:325-9.
23. Allan R, Rodrick M, Knobel HR, Isliker H. Inhibition of the interaction between the complement component C1q and immune complexes. Int Arch Allergy Appl Immunol 1979; 58:140-8.
24. Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation. In: Harker LA, Zimmerman TS, editors. Methods in hematology, measurement of platelet function. Edinburgh: Churchill-Livingstone, 1983:64.
25. Gemmell CH. A flow cytometric immunoassay to quantify adsorption of complement activation products (iC3b, C3d, SC5b-9) on artificial surfaces. J Biomed Mater Res 1997; 37:474-80.
26. Faraday N, Goldschmidt-Clermont P, Dise K, Bray PF. Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry. J Lab Clin Med 1994; 123:728-40.
27. Xia Z, Wong T, Liu Q, Kasirer-Friede A, Brown E, Frojmovic MM. Optimally functional fluorescein isothiocyanate-labelled fibrinogen for quantitative studies of binding to activated platelets and platelet aggregation. Br J Haematol 1996;93:204-14.
28. Chandy T, Sharma CP. Changes in alumin/platelet interaction with an artificial surface due to antibiotics, pyridoxal phosphate, and lymphocytes. Artif Organs 1988;12:143-51.
29. Gemmell CH, Black JP, Yeo EL, Sefton MV. Material-induced up-regulation of leukocyte CD11b during whole blood contact: material differences and a role for complement. J Biomed Mater Res 1996;32:29-35.
30. Salzman EW, Brier-Russell D, Lindon J, Merrill EW. Platelets and artificial surfaces: the effect of drugs. Philos Trans R Soc Lond B Biol Sci 1981;294:389-98.
31. Lam SCT, Harfenist EJ, Packham MA, Mustard JF. Investigations of possible mechanisms of pyridoxal-5-phosphate inhibition of platelet reactions. Thromb Res 1980;20:633-45.
32. Krishnamurthi S, Westwick J, Kakkar VV. Effect of pyridoxal 5′-phosphate (PALP) on human platelet aggregation, dense granule release and thromboxane B2 generation: role of Schiff base formation. Thromb Haemost 1982;48:136-41.